Healthcare
Trinity Biotech plc(TRIB)
Live Price
Offline$0.588
+1.40% today
1Y Change
+1.74%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +8.3%
- EPS Growth
- +44.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trinity Biotech plc (TRIB) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.59 and up 1.7% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +44.8%, a dividend yield of 0.0%. What stands out right now is revenue +8.3%, EPS +44.8%, free cash flow -15.3% with operating margin -40.7% and ROIC -27.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines TRIB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.3% vs +7.6% peer median
Operating Margin
Below sector median
-40.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +8.3% and EPS at +44.8%, with operating margin around -40.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -4.8% | +11.1% | โ |
2026 Jan 2, 2026 | โ | +1.3% | -2.7% | +9.3% |
2025 Dec 23, 2025 | +37.3% | -20.3% | -41.4% | -28.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRIB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TRIB Max Drawdown
-71.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRIB and SPY.
Company Overview
Trinity Biotech plc
NASDAQ Global Select
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
- Leadership
- John Gillard
- IPO Date
- Oct 21, 1992
- Employees
- 380
- Street Address
- IDA Business Park
- Mailing
- Bray, A98 H5C8
- Region
- Bray, IE
- Reporting Currency
- USD
- Investor Line
- 353 1 276 9800
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.1
- Price/Book
- โ
Growth
- Revenue
- +8.3%
- EPS
- +44.8%
- Free Cash Flow
- -15.3%
Profitability
- Gross Margin
- 34.7%
- Operating Margin
- -40.7%
- Net Margin
- -75.9%
- ROE
- 80.7%
- ROIC
- -27.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.